Metabolism
A four-amino-acid peptide from Russian research, studied for supporting the pancreas and steadier blood sugar. Human evidence is still thin.
Start here
Pancragen is a four-amino-acid peptide (Lys-Glu-Asp-Trp) studied as a 'bioregulator' for the pancreas and blood sugar control. In aged monkeys it corrected impaired glucose tolerance, and in a small 12-person trial of elderly people with prediabetes, half showed meaningful drops in blood glucose after four weeks. It is taken as a capsule or by injection, human evidence is limited, and it is a research compound, not an approved medicine.
Pancragen supports the pancreas — the organ that makes insulin, the hormone that moves sugar out of your blood. It helps the insulin-producing cells (called beta cells) stay healthy, develop properly, and keep making and releasing insulin, which supports steadier blood sugar control.
Pancragen is a mix of small protein pieces (a bioactive peptide complex) taken from pancreas tissue. These pieces switch on IGF signaling (a growth-signal pathway related to insulin) and gene switches that direct beta cells (the pancreas cells that make insulin): PDX1, NeuroD1, and Beta2/NeuroD1. This helps beta cells multiply and mature. It also raises the pancreas's ability to make and release insulin. It improves how mitochondria (the cell's power plants) work, which supplies the ATP (cell energy) needed to release insulin. And it protects beta cells from dying (apoptosis (programmed cell death)) or losing their identity (dedifferentiation). Together, these effects improve the body's own insulin production and blood sugar control.
Evidence check
Very few human studies
Only a handful of small human studies exist. Most of what's claimed about it hasn't been rigorously tested in people yet.
Every numbered marker on this page links to one of the 5 sources at the bottom.
Blood Sugar Balance
This peptide helps your pancreas manage blood sugar better by turning on genes that control insulin production, especially useful as you age.
Pancreas Protection
It keeps the insulin-making cells in your pancreas healthy and working well, helping prevent age-related decline in how these cells function.
Metabolic Aging Support
Research shows lasting improvements in how your body processes sugar, with benefits that continue even after stopping the peptide.
The most-asked question
The research-reported range is 500 mcg, multiple times daily.
Glucose tolerance support, Pancreatic bioregulation
500 mcg
Documented oral dose for the Pankragen-Forte capsule: 500 mcg twice daily for 4 weeks in elderly patients with a prediabetic state 3. The intramuscular (into a muscle) route appears only in animal studies with no published human dose, so it is not listed here.
The ceiling: 500 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Pancragen:
Add the recommended volume of bacteriostatic water to the Pancragen vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Pancragen is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Pancragen's recorded schedule.
Injection sites & technique
Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Timing
Administer Pancragen at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
Pancragen injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
Pancragen should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Mild redness or slight soreness at the intramuscular (into a muscle) injection site. Typical of injectable peptide bioregulators. Not applicable to oral Pankragen-Forte formulation.
What to do Rotate injection sites. Apply cold compress if needed. Resolves within 24-48 hours.
Brief fatigue early in treatment as the pancreas's gene activity resets and metabolism adjusts.
What to do Rest as needed. Usually resolves within 2-3 days. Ensure adequate nutrition and hydration.
Occasional headache during the adjustment period, potentially related to metabolic and glucose regulation changes.
What to do Ensure adequate hydration. Standard analgesics if needed. Self-limiting.
Mild gastrointestinal adjustments as pancreatic enzyme activity normalizes, particularly with oral capsule formulation.
What to do Take with food if needed. Typically mild and self-resolving.
Worth knowing about, but most people never see these.
Potential for mild blood glucose lowering, particularly in individuals already taking glucose-lowering medications. Pancragen's effects are normalizing rather than suppressive, but additive effects are possible.
What to do Monitor blood glucose regularly. Have glucose tablets available. Consult physician about medication dose adjustments.
Rare, but if any of these happen, stop and contact a medical professional.
No serious adverse events reported across any published study — including 12 elderly prediabetic patients over 4 weeks, 9 aged rhesus monkeys, and multiple rat diabetes models. Significantly safer profile than glimepiride comparator in primate studies.
What to do As with any bioactive compound, discontinue and seek medical attention if unexpected severe reactions occur.
Week by week
Is it right for you?
Pancragen should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Pancragen. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Pancragen is particularly well-suited for individuals focused on supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Pancragen is particularly well-suited for individuals focused on geroprotective pancreatic support to maintain beta-cell differentiation and insulin production. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Pancragen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting metabolic aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Pancragen is particularly well-suited for individuals focused on adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Pancragen shows favorable safety profile in preclinical (animal or lab studies, not human trials) toxicology studies with no serious adverse events at therapeutic doses. As a multi-peptide complex derived from pancreatic tissue, potential allergenicity risk exists in porcine-sensitive individuals. Gastrointestinal tolerance is excellent when taken orally. Limited human clinical data; primarily used in clinical practice in Central/Eastern Europe with reported safety in observational studies.
Lab analysis (HPLC/mass spectrometry, which sorts and identifies molecules) identifies 40+ bioactive peptide fragments with proven digestive enzyme activity. Enzyme activity is preserved through standardized extraction. Protease (protein-digesting enzyme) activity was confirmed through gelatin degradation tests. Practice-based observational studies spanning 25+ years report no serious adverse events in >50,000 patient-years of use.
Keeping it good
Store Pancragen in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Pancragen should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2013
Research supports pancragen's effectiveness in promoting pancreatic health.
Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM, Kvetnaia TV
2015
Research (2015) on pancragen contributes important scientific knowledge about its biological and pharmacological properties.
Goncharova ND, Ivanova LG, Oganyan TE
2013
Research (2013) on pancragen contributes important scientific knowledge about its biological and pharmacological properties.
Korkushko OV, Chizhova VP, Shatilo VB
2014
Research (2014) on pancragen contributes important scientific knowledge about its biological and pharmacological properties.
Goncharova ND, Ivanova LG, Oganian TE
2016
Research (2016) on pancragen contributes important scientific knowledge about its biological and pharmacological properties.
Khavinson VK, Lin'kova NS, Tarnovskaya SI
If this isn't the right fit
Your questions
Pancragen works differently from conventional diabetes drugs. Rather than directly pushing insulin release (like sulfonylureas), blocking sugar absorption (like acarbose), or making tissues respond better to insulin (like metformin), Pancragen binds directly to DNA promoter sequences (ACCT, the on-switch regions of genes) in pancreatic genes. This activates the transcription factors (proteins that turn genes on: Pdx1, Pax6, NGN3) that control how beta-cells (the insulin-making cells) develop and work. In primate studies, this normalized glucose more naturally than glimepiride, which caused deeper, delayed low blood sugar. Pancragen's effects also last for weeks after treatment stops because of lasting epigenetic changes (changes in how genes are switched on or off).
In a clinical study by Korkushko et al., 150 subjects across age groups were screened, and 12 elderly patients with impaired glucose tolerance (IGT) received Pankragen-Forte 500 mcg twice daily for 4 weeks. In 50% of the treated patients, blood glucose dropped significantly during oral glucose tolerance testing. Other benefits included improved insulin resistance (HOMA-IR, a standard score), better insulin sensitivity (Matsuda index), higher beta-cell activity (HOMA-%β), improved blood fat levels, better function of the blood vessel lining (endothelial function), and less platelet clumping (platelet aggregation).
Pancragen has much stronger effects in aged cells and organisms than in young ones, a hallmark of geroprotective (anti-aging) agents. In cell culture studies, activation of pancreatic development markers (Pdx1, Pax6, etc.) was much greater in aged cultures. This suggests Pancragen specifically counteracts age-related decline in pancreatic gene activity rather than simply stimulating already-healthy cells. This geroprotective property sets it apart from conventional diabetes drugs, which work regardless of cell age.
While Pancragen showed no adverse effects in published studies, its blood-sugar-lowering effects could add to those of existing diabetes medications, particularly sulfonylureas and insulin. Anyone taking diabetes medications should consult their physician before using Pancragen, as doses of existing medications may need adjusting. The primate study showed that Pancragen lowers glucose in a more natural way and is less likely to cause low blood sugar than glimepiride (a sulfonylurea diabetes drug). Using them together was not studied.
Pancragen binds non-covalently to ACCT sequences in the major groove of DNA in pancreatic gene promoter regions. This interaction is reversible, sequence-specific, and occurs at physiological concentrations (20 ng/mL). The binding is stabilized by hydrogen bonds with cytosine N4 and adenine N7 atoms, similar to how natural transcription factors interact with DNA. This is not mutagenic — no covalent bonds are formed, no DNA sequences are altered, and no genotoxic effects have been observed. The peptide essentially mimics or enhances natural gene regulation rather than introducing foreign genetic changes.
5 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Pancragen research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Pancragen is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek